sulfasalazine / Generic mfg. - LARVOL DELTA

Calcineurin inhibitors reduce risk of MGUS progression to multiple myeloma in immunosuppressant users: A retrospective multi-institution cohort study (ASH 2025) - "To ensure maximal consistency across the studied population,both the exposure group and the control group had received at least one of the following IST—azathioprine, leflunomide, cyclophosphamide, methotrexate, sulfasalazine, or mycophenolate mofetil—within 1 year prior to, or any time after, the initial diagnosis of MGUS but before any diagnosis of MM.Patients in CNi group were defined by additional CNi exposure (excluding topical and ophthalmic route)within the same time window, whereas control had never received CNi. These findings support thehypothesis that dampening immune activation may lower the risk of malignant transformation in MGUS.Clinically, this study alleviates concerns regarding the potential oncogenic risks of cytotoxic T cellsuppression in patients with coexisting autoimmune disorders and MGUS. Furthermore, it raises thepotential role of T cell inhibitors as one of the interventions to prevent MGUS progression in broaderpatient populations, warranting..."

Retrospective data • Amyloidosis • Chronic Kidney Disease • Hematological Malignancies • Immunology • Monoclonal Gammopathy • Multiple Myeloma • Nephrology • Ophthalmology • Renal Disease • Solid Organ Transplantation • CD8 • GZMB

Anti-CD19 chimeric antigen receptor T-cell therapy for patients with non-Hodgkin's lymphoma and concurrent autoimmune disease (ASH 2025) - "methotrexate, hydroxychloroquine (HCQ),azathioprine); 9 required biologic/targeted DMARD (ex. adalimumab, etanercept, risankizumab,infliximab, rituximab).DMARDs were weaned prior to CART however 9 pts (37.5%) remained on AID tx at the time of cellcollection, including HCQ (n=4), sulfasalazine/mesalamine (n=2), and 1 each of prednisone, colestipol,sulfasalazine, and apremilast... In this single center study of pts receiving CART for NHL we found no difference in responserates nor survival outcomes in pts with or without AID and therefore propose that AID should notpreclude the use of CART. Lower severity of ICANS was seen in AID pts, though additional study withlarger cohorts is required. The majority of pts were able to taper off AID tx prior to CART, while HCQ wasable to be safely continued throughout CART collection with no apparent effect on CART efficacy."

CAR T-Cell Therapy • Clinical • Ankylosing Spondylitis • B Cell Non-Hodgkin Lymphoma • CNS Disorders • Dermatology • Dermatomyositis • Gastroenterology • Hematological Disorders • Hematological Malignancies • Immunology • Inflammatory Arthritis • Lymphoma • Myasthenia Gravis • Myositis • Non-Hodgkin’s Lymphoma • Psoriasis • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies

DP13 Keep calm and shoulder on: a lesion that can't be shrugged off. (PubMed, Br J Dermatol) - "The second cycle of adjuvant chemotherapy (5-fluorouracil, epirubicin, cyclophosphamide) caused right-upper-limb phlebitis and lymphangitis with permanent damage to local vasculature...She was on hydroxychloroquine for long-standing rheumatoid arthritis, having previously received methotrexate and sulfasalazine...Some cases described in the literature as APL in irradiated areas are possibly the lymphatic subtype of an AVL. As there was no latency between irradiation and onset, our case is more likely APL, rather than AVL outside the field of irradiation."

Journal • Angiosarcoma • Breast Cancer • Epstein-Barr Virus Infections • Immunology • Inflammatory Arthritis • Oncology • Rheumatoid Arthritis • Rheumatology • Sarcoma • Solid Tumor • CD31 • CD34 • MYC • PECAM1

Data-Driven Classification of Solubility Space in Deep Eutectic Solvents: Deciphering Driving Forces Using PCA and K-Means Clustering. (PubMed, Molecules) - "Case studies of Sulfasalazine and Caffeine illustrated how multi-cluster distributions guide formulation strategies, distinguishing precision-requiring from forgiving compounds. This taxonomy provides formulation scientists with a rational framework for DES selection, emphasizing aqueous modification, HBD and HBA diversity, and balanced solvation-interaction optimization. The integrated PCA-clustering approach transforms DES development from trial-and-error screening to targeted design, offering fundamental insights into solubility mechanisms while accelerating sustainable pharmaceutical formulation."

Journal

Autoimmune Outcomes in Patients with Concurrent Autoimmune Disease Receiving CD19 CAR T-Cell Therapy for Lymphoma (ASH 2024) - "Products included axicabtagene ciloleucel (axi-cel), brexucabtagene autoleucel (brexu-cel), lisocabtagene maraleucel (liso-cel), and tisagenlecleucel (tisa-cel)...Medications that were discontinued included hydroxychloroquine, rituximab, and sulfasalazine. The fourth patient, who had paraneoplastic cold agglutinin disease, experienced improvement in symptom burden but remained on sutimlimab (last follow-up 2 months post-CAR T-cell therapy)...CAR T-cell therapy may be a potential treatment option for patients with severe AID. Although our study was limited by a small sample size, these data support prospective trials to determine both the efficacy and toxicity of CAR-T cell therapy for patients with AID."

CAR T-Cell Therapy • Clinical • Anemia • Autoimmune Hemolytic Anemia • CNS Disorders • Complement-mediated Rare Disorders • Dermatology • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Lymphoma • Multiple Myeloma • Multiple Sclerosis • Oncology • Psoriasis • Rheumatoid Arthritis • Rheumatology • Systemic Lupus Erythematosus

Effectiveness of Tofacitinib in Patients with Psoriatic Arthritis Initiating Monotherapy Versus Combination Therapy: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. (PubMed, Rheumatol Ther) - P | "Monotherapy and combination therapy initiators demonstrated improvements across effectiveness outcomes. Tofacitinib monotherapy initiators experienced numerical improvements in overall work impairment/activity impairment. This highlights tofacitinib effectiveness as monotherapy/combination therapy for a diverse PsA population. However, the small sample size limited the statistical power, and so results should be interpreted cautiously."

Journal • Monotherapy • Ankylosing Spondylitis • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis

Comparison of nintedanib outcomes in rheumatoid arthritis associated interstitial lung disease (RA-ILD) and idiopathic pulmonary fibrosis (IPF) (BTS WM 2025) - "These include conventional synthetic DMARDs such as Methotrexate and Sulfasalazine as well as biological agents such as Adalimumab and Rituximab. Our results support Nintedanib delaying progression of disease. We demonstrate a higher rate of treatment cessation in the RA-ILD group than was seen in the INBUILD study warranting more research to understand whether this relates to disease severity at initiation or the co-prescription of DMARDs."

Idiopathic Pulmonary Fibrosis • Immunology • Inflammatory Arthritis • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology

A randomized European multicenter phase 2, double-blind, 2-arm study of sulfasalazine versus placebo combined with stereotactic radiosurgery in recurrent glioblastoma: the STARS trial protocol (SNO 2025) - "Secondary endpoints include overall survival, progression-free survival, quality of life, cognitive function, safety, and patient- and caregiver-reported outcomes related to daily functioning. Exploratory endpoints include changes in tumor and brain GSH levels via MR spectroscopy, metabolic alterations on PET-MRI, xCT expression in archival tumor tissue, correlations between microbiota, immune status, and treatment response, and development of an AI-based predictive model integrating multimodal trial data."

Clinical • P2 data • Surgery • Brain Cancer • Glioblastoma • Glioma • Solid Tumor

New frontiers in rheumatoid arthritis therapy: From classic DMARDs to biologics and beyond. (PubMed, Pathol Res Pract) - "This review provides a detailed overview of the evolving landscape of RA drug development, tracing the progression from conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) such as methotrexate and sulfasalazine, to targeted synthetic DMARDs (tsDMARDs) like JAK inhibitors, and biologic DMARDs (bDMARDs) including TNF and IL-6 antagonists. Despite significant advances, challenges such as incomplete remission rates, variable patient responses, and long-term safety concerns underscore the need for precision medicine and novel therapeutic approaches. This review emphasizes the critical role of immunopathology in guiding RA drug development and the ongoing efforts to achieve personalized, sustained disease control."

Journal • Review • Immunology • Inflammation • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • IL6

A systematic review and pharmacovigilance analysis of the risk of agranulocytosis associated with metamizole use. (PubMed, Sci Rep) - "The reporting odds ratio (ROR) with a 95% confidence interval (95% CI) showed a higher likelihood of reporting agranulocytosis with metamizole compared to clozapine (ROR: 5.50, 95% CI 5.18-5.82), sulfasalazine (ROR: 7.31, 95% CI 6.58-8.14), penicillamine (ROR: 34.4, 95% CI 11.70-167.89), and NSAIDs (ROR: 41.7, 95% CI 38.24-45.52). Our results confirm an increased likelihood of reporting agranulocytosis with metamizole. Given this risk and the availability of safer, effective alternatives, further research is needed."

Adverse events • Journal • Agranulocytosis • Granulocytopenia • Pain

SLC7A11 as a molecular nexus of prognosis, resistance, and therapeutic roadmap in cancer: A systematic review and meta-analysis. (PubMed, Int J Biol Macromol) - "Moreover, SLC7A11 inhibitors, particularly sulfasalazine and erastin, effectively reversed resistance, in 18 clinical trials (Phase I-III) completed over the last decade. Targeting SLC7A11 presents a promising therapeutic strategy to modulate redox balance, metabolism, and ferroptosis, towards efficient cancer treatments."

Journal • Retrospective data • Review • Oncology • SLC7A11

Colon-Specific Delivery of Probenecid Enhances Therapeutic Activity of the Uricosuric Agent Against Rat Colitis. (PubMed, Pharmaceutics) - "Moreover, PBN-GA therapeutically surpassed sulfasalazine, a currently used anti-IBD drug, in rat colitis. These results suggest that amide conjugation with GA can be used to design a colon-targeting prodrug for PBN. Colon-targeted PBN may not only enhance therapeutic effectiveness but also improve the safety of PBN repositioned for the treatment of IBD and may be a pharmacological alternative for current small-molecule anti-IBD drugs with low efficacy or serious adverse effects with long-term use."

Journal • Preclinical • Gastroenterology • Gastrointestinal Disorder • Gout • Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Rheumatology

Dendrobium officinale Polysaccharide Relieves the DSS-Induced Chronic Colitis in C57BL/6J Mice and Regulates Colonic Microflora Structure. (PubMed, Metabolites) - "Eighty-four mice were randomized into seven groups: control, model, low/high-dose leaf-DOP, low/high-dose stem-DOP, and sulfasalazine positive control...Metabolomics further elucidated DOP-mediated regulation of purine and nicotinate/nicotinamide metabolism-pathways mechanistically linked to its anti-inflammatory and barrier-repair effects. DOP effectively alleviates symptoms of DSS-induced chronic colitis in mice, protects intestinal barrier integrity, and achieves therapeutic potential through simultaneous regulation of the gut microbiome and metabolome."

Journal • Preclinical • Gastroenterology • Gastrointestinal Disorder • Immunology • Oncology • OCLN • TJP1 • TNFA

Cost-effectiveness of risk-stratified blood-test monitoring strategies for adults with inflammatory conditions. (PubMed, Rheumatology (Oxford)) - "Extending the interval between monitoring blood-tests appears to be cost-effective with annual monitoring producing consistently good results regardless of assumptions related to risks of AEs, risk decile, or treatment."

HEOR • Journal • Inflammation

Case Report: Pediatric palisaded neutrophilic and granulomatous dermatitis without systemic diseases treated with sulfasalazine. (PubMed, Front Med (Lausanne)) - "Current treatment options for PNGD include oral dapsone, hydroxychloroquine, and intralesional or systemic corticosteroids. Significant lesion resolution was achieved after 2 months of oral sulfasalazine therapy (25 mg/kg/day in divided doses), with only mild abdominal discomfort. To our knowledge, this represents the first successful use of sulfasalazine for PNGD, providing a dapsone-sparing alternative for pediatric PNGD."

Journal • Dermatitis • Dermatology • Immunology • Pediatrics

A randomized European multicenter phase 2, double-blind, 2-arm study of sulfasalazine versus placebo combined with stereotactic radiosurgery in recurrent glioblastoma: the STARS trial protocol (WFNOS 2025) - "Exploratory endpoints include changes in tumor and brain GSH levels via MR spectroscopy, metabolic alterations on PET-MRI, xCT expression in archival tumor tissue, correlations between microbiota, immune status, and treatment response, and development of an AI-based predictive model integrating multimodal trial data. The trial is currently under regulatory and ethical review in nine European Gamma Knife centers and is seeking funding."

Clinical • P2 data • Surgery • Glioblastoma • Glioma • Oncology • Solid Tumor

Different Acupuncture Therapies Combined with Sulfasalazine for the Treatment of Ankylosing Spondylitis: Bayesian Network Meta-Analysis. (PubMed, J Pain Res) - "Du Meridian Moxibustion and Acupuncture and SASP are more effective than Du Meridian Moxibustion and SASP. Based on the results of this study, Acupotomy, Du Meridian Moxibustion and Cupping and SASP combined with SASP have the best effects."

Journal • Retrospective data • Review • Ankylosing Spondylitis • Immunology • Inflammatory Arthritis • Pain • Rheumatology • Seronegative Spondyloarthropathies

Translational Disruption of NRF2 By Zotatifin Enhances Sensitivity to Ferroptosis and CAR-T Cells in Diffuse Large B-Cell Lymphoma (ASH 2024) - "We observed strong synergy, however, between zotatifin and various ferroptosis inducers, including erastin, RSL3, dimethyl formamide (DMF), sulfasalazine (SASP), ML385, and the pharmacokinetically optimized compound imidazole ketone erastin (IKE), while the anti-ferroptotic antioxidant N-acetyl cysteine (NAC) was antagonistic. These results advocate for clinical strategies to enhance investigational ferroptosis inducers and approved CAR-T cells. Further optimization of these regimens holds potential to enhance therapeutic efficacy and overcome resistance mechanisms in DLBCL treatment."

CAR T-Cell Therapy • IO biomarker • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • EIF4A1 • EIF4A2 • IFNG • NFE2L2 • SLC3A2

Development of the FGFR4-ADC bearing the ferroptosis inducer sulfasalazine for hepatocellular carcinoma. (PubMed, iScience) - "This ADC specifically induced ferroptosis in FGFR4-expressing HCC cells and demonstrated FGFR4 expression-dependent anti-tumor activity in xenograft models. The preclinical pharmacokinetics and safety profile of our developed FGFR4-ADC suggest it may represent a pioneering ADC molecule offering a strategy for treating patients with tumor-associated FGFR4 expression."

Journal • Hematological Disorders • Hematological Malignancies • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor • FGFR4

Trichohepatoenteric Syndrome Without Diarrhea: An Atypical Presentation Of Very Early Onset Inflammatory Bowel Disease (ACAAI 2025) - "The patient was started on sulfasalazine and enteral supplementation, with improvement in weight and stool inflammatory markers. Discussion This case highlights the importance of considering monogenic VEO-IBD in infants with syndromic features or immune dysfunction, even in the absence of overt GI symptoms. Early genetic diagnosis allows for tailored therapy and nutritional support, and ongoing multidisciplinary care is essential to address evolving complications and optimize long-term outcomes."

Gastroenterology • Gastrointestinal Disorder • Hepatology • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Pediatrics • Tetanus

Sulfasalazine-Associated Myelodysplastic Syndrome in a 71-Year-Old Patient With Recent-Onset Polyarthritis. (PubMed, Am J Ther) - No abstract available

Journal • Hematological Malignancies • Immunology • Myelodysplastic Syndrome • Oncology

Banxia-Xiexin Decoction Ameliorates Colitis-Associated Colorectal Cancer by Modulating Inflammatory Responses and the Complement and Coagulation Cascade Pathway. (PubMed, J Inflamm Res) - "Mice received BXD at low, medium, and high doses (0.95, 1.9, or 3.8 g/kg/day) by oral gavage from day 21 to day 70, or sulfasalazine (0.6 g/kg/day) as a positive control...BXD may ameliorate CAC by modulating inflammatory responses and glycerophospholipid metabolism, with particular involvement of the complement and coagulation cascades. These findings provide mechanistic insight into the potential anti-CAC effects of BXD and support its further investigation for clinical application."

Journal • Colorectal Cancer • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Metabolic Disorders • Oncology • Solid Tumor • Ulcerative Colitis • IFNG • IL1B • IL6 • TNFA

Sulfasalazine-Induced DRESS and Secondary Hemophagocytic Lymphohistiocytosis (HLH) in Crohn's Disease (ACG 2025) - "She was discharged on dexamethasone taper for forty-one days and a shortened interval of risankizumab. DRESS is a rare condition with an incidence of ~1 in 100,000 hospitalized patients. However, most cases are due to a subset of high-risk medications that all physicians should be able to recognize. This case highlights the need for vigilance of potential drug reactions and their systemic effects and serves to underscore the crucial role of multidisciplinary care in early detection and appropriate treatment of potentially fatal conditions."

Crohn's disease • Dermatology • Eosinophilia • Gastroenterology • Hematological Disorders • Hemophagocytic lymphohistiocytosis • Idiopathic Arthritis • Immunology • Infectious Disease • Inflammatory Arthritis • Inflammatory Bowel Disease • Influenza • Musculoskeletal Pain • Novel Coronavirus Disease • Psoriasis • Psoriatic Arthritis • Rare Diseases • Respiratory Diseases • Respiratory Syncytial Virus Infections • Rheumatology

Sulfasalazine-Induced Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome in Ulcerative Colitis (ACG 2025) - "Treatment involved escalating doses of steroids and cyclosporine until laboratory values stabilized. This case report describes a typical presentation of a rare ADR following five weeks of sulfasalazine for treatment of UC. It is imperative to promptly identify the ADR, remove the culprit medication, and work as a multi-disciplinary team to treat the patient. Careful long-term monitoring for both infectious complications as well as delayed extra-cutaneous manifestations is warranted.Figure: Figure 1: Facial edema with pruritic coalescing erythematous macules and papules on her neckFigure: Figure 2: Pruritic coalescing erythematous macules and papules on her back"

Dermatology • Eosinophilia • Gastroenterology • Gastrointestinal Disorder • Hepatology • Immunology • Inflammatory Bowel Disease • Liver Failure • Ulcerative Colitis

A Novel Association of Danon Disease and Crohn's Disease (ACG 2025) - "Current medications included mycophenolate mofetil and tacrolimus...The patient was started on oral prednisone and sulfasalazine with subsequent symptomatic relief...Several pelvic MRIs following the initial colonoscopy demonstrated chronic perianal fistula over the next two years with treatment failure on sulfasalazine, vedolizumab, adalimumab, and infliximab. Ustekinumab was effective in inducing remission of his CD...The stroke volume index was 57.4 cc. Ejection fraction was 66.6% and the cardiac index was 3.8 L per min per m squared."

Alzheimer's Disease • Cardiomyopathy • Cardiovascular • Cognitive Disorders • Crohn's disease • Cytomegalovirus Infection • Gastroenterology • Gastrointestinal Disorder • Hypertrophic Cardiomyopathy • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • LAMP2